Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Amer Zeidan, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Mika Kontro, Naval Daver

Blood (2025) 146 (Supplement 1): 236.

https://doi.org/10.1182/blood-2025-236

Published: 2025

Journal Articles

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

Mika Kontro, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Amer Zeidan, Naval Daver

Blood (2025) 146 (Supplement 1): 5627.

https://doi.org/10.1182/blood-2025-5627

Published: 2025

Journal Articles

ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial

Daniel Wiseman, Jak Laight, Rebecca Boucher, Chhaya Sankhalpara, Rebecca Record, Jennifer Byrne, Onima Chowdhury, Dominic Culligan, Nicholas Cunningham, Srinivasan Narayanan, Rob Sellar, Kiran Batta, Manoj Raghavan, Dr. Emma Searle, Catherine Cargo, Steve Knapper, Austin Kulasekararaj

Blood (2025) 146 (Supplement 1): 488.

https://doi.org/10.1182/blood-2025-488

Published: 2025

Journal Articles

MLLT1/3 targeted protein degradation as the best-in-class approach for targeting the super elongation complex (SEC) in acute leukemia, including menin inhibitor refractory disease

Alison Maloney, Gilbert Ansa, Graham Craggs, Gillian Farnie, Matthew Fawkes, Fenella Gross, Joe Harman, Sarah Major, Thomas Milne, Ryan Robinson, Dr. Emma Searle, Iain Simpson, Alastair Smith, Tim Somervaille, John Pollard

Blood (2025) 146 (Supplement 1): 320.

https://doi.org/10.1182/blood-2025-320

Published: 2025

Journal Articles

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Blood (2025) 146 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2025-2282

Published: 2025

Journal Articles

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4035.

https://doi.org/10.1182/blood-2025-4035

Published: 2025

Journal Articles

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies

Dr. Emma Searle, Tomasz Knurowski, Sarah Gooding, Victoria Campbell, Sally Moore, Aristeidis Chaidos, Jennifer Travers, Thomas Creasey, Karen Clegg, Tim Somervaille, Charlotte Pawlyn

Blood (2025) 146 (Supplement 1): 8242.

https://doi.org/10.1182/blood-2025-8242

Published: 2025

Journal Articles

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Jenny O'Nions, Andrew Wei, Jordi Esteve, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Hartmut Döhner, Amber D'Souza, James Dugan, Amir Fathi, Pasquale Fedele, Lucille Ferrante, Rachel Kobos, Ana Garrido, Sara Garrido Paniagua, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Danielle Trancucci, Naa Sackey, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Christian Recher, Christoph Röllig, Olga Salamero, Prathap Nagaraja Shastri, Tim Sauer, Dr. Emma Searle, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Uwe Platzbecker, Sylvain Garciaz

Blood (2025) 146 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2025-5200

Published: 2025

Journal Articles

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Hartmut Döhner, Andre Schuh, Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso-Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Della Porta, Amber D'Souza, James Dugan, Jordi Esteve, Amir Fathi, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Olga Salamero, Christina Drenberg Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Daniel Morillo, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sara Garrido Paniagua, Naa Sackey, Tim Sauer, Dr. Emma Searle, Prathap Nagaraja Shastri, Danielle Trancucci, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Paresh Vyas, Andrew Wei, Christoph Röllig

Blood (2025) 146 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2025-5199

Published: 2025

Journal Articles

Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

Vismay Deshani, H Hemat, Adrian Bloor, Mike Dennis, Alex Peel, Adam Jeans, Anna Z Castleton, Emma Searle, Daniel H Wiseman, Mark Williams, Richard Chasty, Ahmed Abdulgawad, Tim Somervaille, John Murray, Jane Robertson, James Cavet, Samar Kulkarni

Blood (2024) 144 (Supplement 1): 7897.

https://doi.org/10.1182/blood-2024-198526

Published: 2024

Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood (2024) 144 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2024-200333

Published: 2024

Journal Articles

Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Samar Kulkarni, Adrian Bloor, Mike Dennis, Anna Z Castleton, Mark Williams, Ahmed Abdulgawad, Tim Somervaille, Daniel H Wiseman, Vismay Deshani, Emma Searle, Angie Leather, John Murray, Sally Pickering, James Cavet

Blood (2024) 144 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2024-211021

Published: 2024

Journal Articles

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Blood (2024) 144 (Supplement 1): 658.

https://doi.org/10.1182/blood-2024-200925

Published: 2024

Journal Articles

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Blood (2024) 144 (Supplement 1): 495.

https://doi.org/10.1182/blood-2024-200181

Published: 2024

Journal Articles

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher, Jenny O'Nions, Ibrahim Aldoss, Ana Alfonso Pierola, Alicia Allred, Juan Manuel Alonso-Dominguez, Laura Barreyro, Pierre Bories, Martin Curtis, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D'Souza, James P. Dugan, Jordi Esteve Reyner, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Sylvain Garciaz, Ana Garrido, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Hagop M. Kantarjian, Marina Konopleva, Jan Krönke, Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Daniel Morillo Giles, Joseph Murphy, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Uwe Platzbecker, Sravanti Rangaraju, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Emma Searle, Natalia Tovar, Trevor Tucker, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Andrew Wei

Blood (2024) 144 (Supplement 1): 215.

https://doi.org/10.1182/blood-2024-207072

Published: 2024

Journal Articles

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Blood (2024) 144 (Supplement 1): 212.

https://doi.org/10.1182/blood-2024-207106

Published: 2024

Journal Articles

Phase 1/2, Open-Label, Multi-Center Study Assessing the Safety, Tolerability and Preliminary Efficacy of CD123 Natural Killer Cell Engager (NKCE), SAR443579, in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy

Anthony S. Stein, Emma Searle, Sylvain Garciaz, Uma Borate, Kyle Jensen, Asma Kefsi, Marie Bernardo, Yue Yang, Sarah Cooley, Ashish Bajel

Blood (2024) 144 (Supplement 1): 2883.3.

https://doi.org/10.1182/blood-2024-205923

Published: 2024

Journal Articles

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Liam Tremble, Paula Maguire, Jiwon Yang, James G Keck, Laura Maher, Mark Graham, Martin F Kaiser, Emma Searle, Mark Sumeray

Blood (2024) 144 (Supplement 1): 2061.

https://doi.org/10.1182/blood-2024-204734

Published: 2024

Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Blood (2024) 144 (Supplement 1): 677.

https://doi.org/10.1182/blood-2024-198403

Published: 2024

Journal Articles

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Nirav N. Shah, Zulfa Omer, Graham P. Collins, Francesco Forconi, Alexey Danilov, John C. Byrd, Dima El-Sharkawi, Emma Searle, Alvaro J Alencar, Shuo Ma, Sarah Injac, Talha Munir

Blood (2024) 144 (Supplement 1): 884.

https://doi.org/10.1182/blood-2024-194839

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial

MLLT1/3 targeted protein degradation as the best-in-class approach for targeting the super elongation complex (SEC) in acute leukemia, including menin inhibitor refractory disease

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only